Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00523939 · ClinicalTrials.gov registry record · Phase 2
DepoCyt for Active Lymphomatous or Leukemic Meningitis
A Phase 2 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00523939 is a Phase 2 study that was terminated before completion, run by Duke University. The registered enrollment target is 4 participants.
The verdict
NCT00523939, a Phase 2 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the response rate of lymphomatous meningitis or leukemic meningitis to DepoCyt. The safety of DepoCyt, the number of people who respond well to the study drug, and the response of symptoms to the study drug will also be determined.
Interventions
- DRUG cytarabine liposome injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2006-06 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00523939
The ClinicalTrials.gov registry entry for NCT00523939 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cytarabine liposome injection is the first listed.
NCT00523939 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00523939 about?
NCT00523939 is a clinical study titled "DepoCyt for Active Lymphomatous or Leukemic Meningitis". The purpose of this study is to determine the response rate of lymphomatous meningitis or leukemic meningitis to DepoCyt. The safety of DepoCyt, the number of people who respond well to the study drug, and the response of symptoms to the study drug will also be determined.
What is the current status of trial NCT00523939?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2006-06. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00523939?
The interventions under investigation include: cytarabine liposome injection (DRUG).
Who is sponsoring clinical trial NCT00523939?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.